World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
76
Citations
31236
World Ranking
18635
National Ranking
9282

Overview

Craig L. Leonardi is affiliated with Saint Louis University in the United States. Their research primarily focuses on the field of Medicine with a strong emphasis on Immunology and Microbiology. Within these broad domains, their work covers multiple subfields including Immunology, Dermatology, Pathology and Forensic Medicine, Economics and Econometrics, and Oncology.

Leonardi's research extensively addresses topics related to Psoriasis, including its treatment and pathogenesis. Other significant topics in their work include Dermatology and Skin Diseases, Autoimmune Bullous Skin Diseases, Health Systems, Economic Evaluations, Quality of Life, Biosimilars and Bioanalytical Methods, Pharmaceutical Studies and Practices, and Drug-Induced Adverse Reactions.

The scientist has published in several reputable venues with multiple contributions. Frequent publication venues include:

  • Journal of the American Academy of Dermatology
  • Dermatology and Therapy
  • Journal of Psoriasis and Psoriatic Arthritis
  • Advances in Therapy
  • JAMA Dermatology

Several recent papers authored or coauthored by Leonardi demonstrate their ongoing engagement in clinical research related to psoriasis and dermatologic therapies. Notable publications include:

  • "Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management of psoriasis with systemic nonbiologic therapies," 2020, Journal of the American Academy of Dermatology
  • "Joint AAD-NPF Guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measures," 2020, Journal of the American Academy of Dermatology
  • "Efficacy and Safety of Continuous Risankizumab Therapy vs Treatment Withdrawal in Patients With Moderate to Severe Plaque Psoriasis," 2020, JAMA Dermatology
  • "Efficacy and Safety of Ixekizumab Through 5 Years in Moderate-to-Severe Psoriasis: Long-Term Results from the UNCOVER-1 and UNCOVER-2 Phase-3 Randomized Controlled Trials," 2020, Dermatology and Therapy
  • "Efficacy of Bimekizumab and Other Biologics in Moderate to Severe Plaque Psoriasis: A Systematic Literature Review and a Network Meta-Analysis," 2022, Dermatology and Therapy

Leonardi frequently collaborates with other researchers in the field. Frequent coauthors include Russel Burge, Mark Lebwohl, April W. Armstrong, Andrew Blauvelt, and Kim Papp.

Best Publications

  • Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)

    Craig L Leonardi;Alexa B Kimball;Kim A Papp;Newman Yeilding

  • Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics

    Alan Menter;Alice Gottlieb;Steven R. Feldman;Abby S. Van Voorhees

  • Etanercept as monotherapy in patients with psoriasis

    Craig L. Leonardi;Jerold L. Powers;Robert T. Matheson;Bernard S. Goffe

  • Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial

    Stephen Tyring;Alice Gottlieb;Kim Papp;Ken Gordon

  • Brodalumab, an Anti–Interleukin-17–Receptor Antibody for Psoriasis

    Kim A Papp;Craig Leonardi;Alan Menter;Jean-Paul Ortonne

  • Anti-Interleukin-17 Monoclonal Antibody Ixekizumab in Chronic Plaque Psoriasis

    Craig Leonardi;Robert Matheson;Claus Zachariae;Gregory Cameron

  • Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: Overview and guidelines of care for treatment with an emphasis on the biologics

    Alice Gottlieb;Neil J. Korman;Kenneth B. Gordon;Steven R. Feldman

  • A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis.

    Gerald G. Krueger;Richard G. Langley;Craig Leonardi;Newman Yeilding

  • Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial

    Alan Menter;Stephen K. Tyring;Kenneth Gordon;Alexa B. Kimball

  • European S3-guidelines on the systemic treatment of psoriasis vulgaris

    D Pathirana;AD Ormerod;P Saiag;Catherine Smith

  • Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics.

    Alan Menter;Bruce E. Strober;Daniel H. Kaplan;Dario Kivelevitch

  • Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis

    Kenneth B Gordon;Jean-Frederic Colombel;Dana S Hardin

  • Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study

    Kenneth B. Gordon;Richard G. Langley;Craig Leonardi;Darryl Toth

  • Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1)

    Kim Papp;Kristian Reich;Craig L. Leonardi;Leon Kircik

  • Guidelines of care for the management of psoriasis and psoriatic arthritis: section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions.

    Alan Menter;Neil J. Korman;Craig A. Elmets;Steven R. Feldman

  • Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities

    Craig A. Elmets;Craig L. Leonardi;Dawn M.R. Davis;Joel M. Gelfand

  • Risk of Serious Infection With Biologic and Systemic Treatment of Psoriasis: Results From the Psoriasis Longitudinal Assessment and Registry (PSOLAR).

    Robert E. Kalb;David F. Fiorentino;Mark G. Lebwohl;John Toole

  • A classification of psoriasis vulgaris according to phenotype

    C. E M Griffiths;E. Christophers;J. N W N Barker;R. J G Chalmers

  • Guselkumab (an IL-23–specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasis

    Howard Sofen;Stacy Smith;Robert T. Matheson;Craig L. Leonardi

  • Secukinumab long-term safety experience: A pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis

    Peter C.M. van de Kerkhof;Christopher E.M. Griffiths;Kristian Reich;Craig L. Leonardi

Frequent Co-Authors

Kenneth B. Gordon
Kenneth B. Gordon Medical College of Wisconsin
Alice B. Gottlieb
Alice B. Gottlieb Icahn School of Medicine at Mount Sinai
Mark Lebwohl
Mark Lebwohl Icahn School of Medicine at Mount Sinai
Kim Papp
Kim Papp Probity Medical Research
Alan Menter
Alan Menter Texas A&M University
Andrew Blauvelt
Andrew Blauvelt Veterans Health Administration
Kristian Reich
Kristian Reich University of Göttingen
Richard G. Langley
Richard G. Langley Dalhousie University
Craig A. Elmets
Craig A. Elmets University of Alabama at Birmingham
Christopher E.M. Griffiths
Christopher E.M. Griffiths University of Manchester

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Pursuing a medical degree in the USA often leads to a variety of career options, both clinical and non-clinical. For those interested in healthcare leadership, a health administration degree prepares graduates for roles in hospital management, policy analysis, and healthcare consulting.

If you are looking to advance further, there are many affordable mha online programs designed for future healthcare executives. These courses focus on strategic planning, finance, and organizational leadership in healthcare settings.

For registered nurses, msn to dnp programs online offer a streamlined path to a Doctor of Nursing Practice, enabling advanced practice, leadership, and teaching roles.

Pharmacists can also earn advanced qualifications with flexible pharmd online programs, expanding their expertise and career opportunities in clinical or research settings.

These options can help broaden your impact on the healthcare industry—even beyond direct patient care.

Best Scientists Citing Craig L. Leonardi

Trending Scientists